Skip to main content

Table 5 Results from subgroup analyses

From: Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece

Subgroup Standard care Ivabradine + Standard care Incremental costs & outcomes
Total costs (in €) Total QALYs Total costs (in €) Total QALYs Costs (in €) LYs QALYs Cost/LY (in €) Cost/QALY (in €)
All patients (HR ≥ 75 b.p.m.) 5,873 3.99 8,665 4.27 2,792 0.25 0.28 11,002 9,986
Age < 75 years 6,033 4.14 8,932 4.43 2,899 0.27 0.29 10,897 9,909
Age ≥ 75 years 4,350 2.54 6,123 2.69 1,772 0.14 0.16 12,944 11,355
NYHA II 6,358 4.55 9,498 4.84 3,140 0.24 0.28 12,935 11,112
NYHA III 5,528 3.55 8,059 3.83 2,531 0.27 0.28 9,542 9,044
NYHA IV 3,383 1.79 4,726 2.00 1,343 0.22 0.21 6,018 6,445
HF duration <0.6 years 6,683 5.02 10,063 5.35 3,379 0.28 0.33 12,085 10,287
HF duration ≥0.6 < 2 years 5,881 4.10 8,752 4.39 2,871 0.26 0.29 10,919 9,883
HF duration ≥2 < 4.8 years 5,489 3.66 8,138 3.92 2,648 0.24 0.26 10,916 10,168
HF duration ≥4.8 years 5,466 3.20 7,755 3.44 2,290 0.23 0.24 9,931 9,527
No beta blocker 5,144 3.08 7,384 3.39 2,240 0.31 0.31 7,239 7,267
Beta blocker < half target dose 5,481 3.60 7,992 3.87 2,511 0.25 0.27 9,942 9,250
Beta blocker = > half target dose < target dose 6,338 4.45 9,438 4.73 3,100 0.24 0.28 12,794 11,115
Beta blocker = > target dose 6,440 4.64 9,684 4.92 3,244 0.24 0.28 13,602 11,619
LVEF < 26% 5,407 3.31 7,709 3.60 2,302 0.28 0.29 8,356 8,072
LVEF ≥26% < 30% 5,483 3.66 8,052 3.94 2,569 0.25 0.27 10,163 9,440
LVEF ≥30 < 33% 5,993 4.19 8,947 4.47 2,955 0.26 0.28 11,558 10,400
LVEF ≥ 33% 6,443 4.64 9,688 4.92 3,245 0.23 0.27 13,977 11,807
Non-diabetic 5,746 4.04 8,577 4.32 2,831 0.25 0.28 11,210 10,112
Diabetic 6,150 3.86 8,859 4.14 2,709 0.26 0.28 10,556 9,710
No prior CAD 5,839 4.20 8,719 4.52 2,880 0.29 0.32 9,907 9,051
Prior CAD 5,887 3.90 8,643 4.16 2,756 0.24 0.26 11,549 10,448
  1. HR: Heart rate; CAD: coronary artery disease; HF: Heart Failure; LY: life Years; QALY: Quality-adjusted-life year; NYHA: New York Heart Association; LVEF: Left Ventricular Ejection Fraction.